Last reviewed · How we verify
erythropoietin beta
Erythropoietin beta stimulates erythroid progenitor cells in bone marrow to increase red blood cell production and hemoglobin levels.
Erythropoietin beta stimulates erythroid progenitor cells in bone marrow to increase red blood cell production and hemoglobin levels. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Anemia in patients with cancer.
At a glance
| Generic name | erythropoietin beta |
|---|---|
| Also known as | erythropoietin, epoetin, NeoRecormon |
| Sponsor | University of Cambridge |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Erythropoietin beta is a recombinant form of the naturally occurring hormone erythropoietin (EPO), which binds to the erythropoietin receptor on erythroid progenitor cells. This binding activates intracellular signaling pathways that promote proliferation, differentiation, and maturation of red blood cell precursors. The result is increased hemoglobin and hematocrit levels, improving oxygen-carrying capacity of blood.
Approved indications
- Anemia of chronic kidney disease
- Chemotherapy-induced anemia
- Anemia in patients with cancer
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Injection site reactions
- Pure red cell aplasia
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Vafseo Outcomes In-Center Experience (PHASE3)
- Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy (PHASE3)
- A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India (PHASE4)
- Correction of Anaemia and Progression of Renal Failure on Transplanted Patients (PHASE4)
- A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA. (PHASE3)
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. (PHASE3)
- Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |